8-K: Aptevo Therapeutics Faces Nasdaq Delisting Threat, Announces Reverse Stock Split and Files Prospectus Supplement

Aptevo Therapeutics received a Nasdaq notification regarding non-compliance with minimum stockholders' equity requirements and is implementing a reverse stock split while also offering shares under an existing agreement.

Summary

• Aptevo Therapeutics received a notification from Nasdaq on May 22, 2025, indicating non-compliance with Nasdaq Listing Rule 5550(b)(1) due to a stockholders' deficit of $1,473,000 reported in the quarterly report for the period ended March 31, 2025.
• The company has 45 days, until July 7, 2025, to submit a plan to regain compliance, and if accepted, could be granted up to 180 days from May 22, 2025, until November 18, 2025, to demonstrate compliance.
• There is no guarantee that Aptevo will regain compliance or that Nasdaq will accept their plan.
• Aptevo filed a prospectus supplement on May 22, 2025, related to the offering and sale of common stock with an aggregate offering price of up to $3,015,515 under its existing At The Market Offering Agreement.
• As of the date of the Prospectus Supplement, the Company had issued and sold 7,989,040 shares of Common Stock pursuant to the Sales Agreement for aggregate gross sale proceeds of $3,349,104.
• The company announced a 1-for-20 reverse stock split, expected to be effective on May 23, 2025, at 5:01 p.m. Eastern Time, with trading on a split-adjusted basis beginning May 27, 2025.
• The reverse stock split aims to maintain compliance with Nasdaq listing standards.
• The reverse stock split will reduce the number of outstanding shares from approximately 13.5 million to approximately 0.7 million, subject to adjustment.

Sentiment

Score: 4

Explanation: The sentiment is negative due to the Nasdaq non-compliance notice and the need for a reverse stock split, but there are some positives in the company's efforts to regain compliance and raise capital.

Positives

• Aptevo is taking steps to regain compliance with Nasdaq listing requirements by submitting a compliance plan.
• The company has the option to appeal any delisting determination by Nasdaq.
• The reverse stock split is intended to help maintain compliance with Nasdaq listing standards.
• The company has an existing At The Market Offering Agreement to raise capital.

Negatives

• Aptevo is currently not in compliance with Nasdaq's minimum stockholders' equity requirement.
• There is no assurance that the company will regain compliance with Nasdaq listing requirements.
• There is no guarantee that Nasdaq will accept the company's compliance plan.
• The company reported a stockholders' deficit of $1,473,000.

Risks

• Failure to regain compliance with Nasdaq listing requirements could result in delisting.
• Nasdaq may not accept the company's plan to regain compliance.
• The reverse stock split could negatively impact the stock price.
• The company's ability to raise capital under the At The Market Offering Agreement is subject to market conditions.

Future Outlook

The company intends to take all reasonable measures to regain compliance with Nasdaq Listing Rules and remain listed on Nasdaq, but there is no assurance of success.

Management Comments

• The Reverse Stock Split is part of the Company's plan to maintain compliance with the continued listing standards of The Nasdaq Capital Market, among other benefits.

Industry Context

Biotech companies, especially clinical-stage ones, often face challenges in maintaining financial compliance with stock exchange listing requirements due to high R&D costs and uncertain revenue streams. Reverse stock splits and at-the-market offerings are common strategies employed to address these issues.

Comparison to Industry Standards

• Many small-cap biotech companies with limited revenue, such as XOMA Corporation prior to its restructuring, have faced similar Nasdaq compliance issues.
• Reverse stock splits are frequently used by companies like Ocugen Inc. (OCGN) to increase their stock price and meet minimum listing requirements.
• At-the-market offerings are a common financing tool, similar to those used by companies like Agenus Inc. (AGEN), to raise capital without significant dilution.

Stakeholder Impact

• Shareholders will be affected by the reverse stock split, which will reduce the number of shares they own.
• The reverse stock split and potential delisting could negatively impact shareholder value.
• Employees may be concerned about the company's financial stability and future prospects.
• The company's ability to fund its clinical programs could be affected by its financial situation.

Next Steps

• Aptevo must submit a plan to Nasdaq by July 7, 2025, to regain compliance.
• The company will implement a 1-for-20 reverse stock split, effective May 23, 2025.
• The company will continue to offer shares under its At The Market Offering Agreement.
• The company plans to file a Current Report on Form 8-K following the Effective Time.

Key Dates

Keywords

Nasdaq, compliance, reverse stock split, stockholders equity, delisting, prospectus supplement, common stock, Aptevo Therapeutics, APVO